Anixa Biosciences (NASDAQ:ANIX) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a hold rating to a sell rating in a report published on Sunday morning.

Several other equities analysts have also issued reports on ANIX. Weiss Ratings reissued a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, February 4th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

Anixa Biosciences Trading Down 1.0%

ANIX stock opened at $2.83 on Friday. The firm has a market cap of $94.89 million, a PE ratio of -8.58 and a beta of 0.48. The stock has a 50-day moving average price of $3.03 and a 200-day moving average price of $3.55. Anixa Biosciences has a 1-year low of $2.33 and a 1-year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. On average, analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Arnold M. Baskies purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were acquired at an average cost of $3.04 per share, with a total value of $30,400.00. Following the purchase, the director owned 135,000 shares in the company, valued at $410,400. This represents a 8.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC acquired a new position in shares of Anixa Biosciences during the second quarter worth approximately $33,000. Cetera Investment Advisers acquired a new stake in Anixa Biosciences in the 4th quarter valued at $35,000. Northwestern Mutual Wealth Management Co. grew its position in Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. bought a new stake in Anixa Biosciences during the 2nd quarter valued at $37,000. Finally, Millennium Management LLC bought a new stake in Anixa Biosciences during the 4th quarter valued at $38,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.